- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03273062
A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury
A Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Cognition and Neuropsychiatric Symptoms in Patients With a History of Acquired Brain Injuries
This is a follow-up study for an ongoing open label trial conducted by the Sheppard Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT) inhibitor Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in patients with brain injuries (BI).
In this study, investigators will conduct a double-blind, placebo-controlled clinical trial utilizing a crossover design to study the effects of two weeks of Tolcapone 200mg administered three times a day (total of 600mg/day) on cognitive performance. Physical, emotional, cognitive and social functioning will also be evaluated through participant and proxy report. The investigators are planning to randomize a total of 12 patients with a history of acquired brain injury (BI).
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
The proposed study is a follow-up study for an ongoing open label trial conducted by the Sheppard Pratt-Lieber Research Institute utilizing the catechol-O-methyl-transferase (COMT) inhibitor Tolcapone to evaluate its effects on cognition and neuropsychiatric symptoms in patients with brain injuries (BI).
The outcome measures utilized in this study were chosen based on the available data from the currently ongoing open-label clinical trial. The proposed study will utilize the same study medication at the same dose and frequency. In addition, the length of administration of study medication (two weeks) is identical. In the proposed study, investigators will conduct a double-blind, placebo-controlled clinical trial utilizing a crossover design to study the effects of two weeks of Tolcapone 200mg administered three times a day (total of 600mg/day) on cognitive performance. Physical, emotional, cognitive and social functioning will be evaluated through participant and proxy report. The investigators are planning to randomize a total of 12 patients with BI.
The cross-over design requires two 2-week long study periods during which the participant receives either Tolcapone two 100mg capsules three times a day (total of 600mg/day) or placebo. Participants will be randomly assigned to two sequence groups either starting with Tolcapone treatment (T-P group) or placebo (P-T group). Investigators and participants will be blind to the study group assignment and hence blind to the treatment (Tolcapone vs. placebo) that subjects receive at a given time. The study periods are separated by a "washout period" that is at least two weeks and maximally 4 weeks long to reduce the potential for carryover effects. Patient reported outcomes will be obtained a total of four times, twice prior to the start of each respective study period (Pre-Study Period Visits I & II) as well as at the end of each study period (Outcome Measures Visits I & II). Cognitive outcome measures will be obtained twice throughout the study, at the end of each respective study period (Outcome Measures Visits I & II).
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Robert J Schloesser, MD
- Telefonnummer: 410-938-4610
- E-mail: rschloesser@sheppardpratt.org
Undersøgelse Kontakt Backup
- Navn: Emily A Berich, BS
- Telefonnummer: 410-938-4610
- E-mail: eberich@sheppardpratt.org
Studiesteder
-
-
Maryland
-
Towson, Maryland, Forenede Stater, 21204
- Rekruttering
- Sheppard Pratt Health System
-
Kontakt:
- Robert J Schloesser, MD
- Telefonnummer: 410-938-4666
- E-mail: rscloesser@sheppardpratt.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Capacity for written informed consent
- Ages 18-70 years, inclusive
- Diagnosis of a BI including mild, moderate, or severe TBI, or other acquired BI and post-BI development of neuropsychiatric complaints.
- Index event resulting in Traumatic or Acquired Brain Injury occurred >12 months prior to trial initiation
- A current or former patient at the clinics of the Sheppard Pratt Neuropsychiatry Program or another Sheppard Pratt outpatient clinic with medical documentation of BI
- Proficient in the English language
- Available to come to Sheppard Pratt Towson for the baseline evaluation and testing and for the duration of the protocol
- Stable neurological and psychiatric symptomatology for two months prior to trial initiation as determined by the referring Sheppard Pratt physician.
- Stable medication dose and regimen for two months prior to trial initiation (based on a review of medical chart)
Exclusion Criteria:
- History of, or active, liver disease or abnormal liver function tests-if the patient currently has elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) levels that exceed 2 times the upper limit of normal [Normal Reference Ranges ALT (Male: 4-40 IU/L, Female: 4-40 IU/L), AST (Male: 4-31 IU/L, Female: 4-37 IU/L) or the ratio of AST: ALT has exceeded 2:1
- Uncontrolled hypo-or hypertension based on Joint National Committee criteria (JNC7) Hypotension: Systolic <90mmHg or diastolic <60mmHg Hypertension: Systolic >140mmHg or diastolic >90 mmHg)
- Active alcohol use disorder, as defined by DSM-5, of any severity mild, moderate, or severe
- Active illicit substance use, resulting in a substance use disorder as defined by DSM-5, of any severity mild, moderate, or severe
- Patient is currently taking Tolcapone or any of the following medications that can interact with Tolcapone resulting in an adverse event: another COMT inhibitor, benserazide, α-methyldopa, Dobutamine, Apomorphine, Isoproterenol, Clozapine, MAO inhibitor
- Known allergy or serious adverse reaction to Tolcapone
- Participated in any investigational drug trial within the past 30 days.
- Pregnant or planning to become pregnant during the study period
- Breastfeeding or planning to breastfeed during the study period.
- Presence of severe pre-morbid/pre-BI cognitive impairment or behavioral dysfunction, as per informant or medical documentation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Study Period 1
15 days of Tolcapone 200mg TID OR Placebo Comparator 15 days of Placebo pill TID |
Tolcapone 200 MG TID
Andre navne:
Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
|
Placebo komparator: Study Period 2
15 days of Placebo pill TID OR Active Comparator 15 days of Tolcapone 200mg TID |
Tolcapone 200 MG TID
Andre navne:
Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
NIH Toolbox Fluid Cognitive Battery
Tidsramme: Administered on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
This battery is a measure of cognitive performance derived from a battery of five cognitive assessments.
|
Administered on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
TBI Quality-of-Life Measurement System
Tidsramme: Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
A patient reported outcome measure assessing physical, emotional, cognitive and social functioning.
Quality of Life Measure is a computer adaptive questionnaire.
|
Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Frontal Systems Behavior Scale
Tidsramme: Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
A patient reported outcome measure, and proxy reported outcome measure, assessing neuropsychiatric symptoms associated with prefrontal cortical dysfunction
|
Administered prior to the start of Tolcapone oe Placebo treatment (i.e. during each Pre-Study Visit) and on the 14th day of Tolcapone or Placebo treatment (i.e. during each Outcome Measures Visit).
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Robert J Schloesser, MD, Sheppard Pratt Health System
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Hjerneskade, kronisk
- Kraniocerebralt traume
- Traumer, nervesystemet
- Hjerneskader
- Sår og skader
- Hjerneskader, traumatiske
- Hjerneskade, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antiparkinson-midler
- Midler mod dyskinesi
- Catechol O-Methyltransferase-hæmmere
- Tolcapone
Andre undersøgelses-id-numre
- 1087860-3
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hjerneskader
-
Assistance Publique Hopitaux De MarseilleUkendt
-
National Institute of Mental Health (NIMH)AfsluttetKÆLEDYR | Brain Imaging | Cannabinoid | CB1Forenede Stater
-
GE HealthcareAfsluttetBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Mayo ClinicTilmelding efter invitationBrain Imaging | Billedbehandling af hele kroppenForenede Stater
-
Tang-Du HospitalIkke rekrutterer endnuPsykisk lidelse | Sociale medier | Brain Imaging
-
University Hospital TuebingenAfsluttetFunktionel dyspepsi | Mad | Brain ImagingTyskland
-
University of MichiganAfsluttetÆndringer i Brain Network ConnectivityForenede Stater
-
School of Health Sciences GenevaUniversity of Lausanne Hospitals; University of Geneva, SwitzerlandRekrutteringMR scanning | Opførsel | Funktionel magnetisk resonansbilleddannelse | Musik | Udvikling, barn | Brain Imaging | Executive funktioner | Hjerneplasticitet | Interventioner | Kunst | Strukturel hjerneforbindelseSchweiz
-
Rigshospitalet, DenmarkLundbeck Foundation; Filadelfia Epilepsy Hospital; Lennart Grams Mindefond...AfsluttetKirurgi | Refraktær epilepsi | Elektroencefalografi | Brain ImagingDanmark
-
Sándor BeniczkyHospital del Mar; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Motol... og andre samarbejdspartnereAktiv, ikke rekrutterendeKirurgi | Refraktær epilepsi | Elektroencefalografi | Brain ImagingSpanien, Portugal, Østrig, Tjekkiet, Danmark, Tyskland, Italien, Rumænien
Kliniske forsøg med Tolcapone 200 MG
-
Yuhan CorporationAfsluttet
-
Mylan Pharmaceuticals IncAfsluttetSund og raskForenede Stater
-
Novartis PharmaceuticalsRekrutteringIkke-småcellet lungekarcinomIndien
-
Atabay Kimya Sanayi Ticaret A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiAfsluttet
-
Novelfarma Ilaç San. ve Tic. Ltd. Sti.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiAfsluttet
-
Gannex Pharma Co., Ltd.Ascletis Pharmaceuticals Co., Ltd.RekrutteringAvancerede solide tumorerForenede Stater
-
World Medicine ILAC SAN. ve TIC. A.S.Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiAfsluttet
-
University of Witwatersrand, South AfricaBill and Melinda Gates FoundationRekruttering
-
Stephen Bagley, MD, MSCEUniversity of Pennsylvania; Abramson Cancer Center at Penn MedicineAktiv, ikke rekrutterende
-
CVI PharmaceuticalsUkendt